Pfizer’s All-Comers CRPC Dream For Talzenna Quashed For Lack Of Biomarker-Negative Rigor

 
• By Bridget Silverman
  
Pfizer's analysis of the TALAPRO-2 trial is like "somebody shooting an arrow at the wall and then painting a target around it," the FDA's Richard Pazdur said. (Shutterstock)

More from US Advisory Committees

More from Geography